Experienced in Neurotoxicity Syndromes

Ulf Petrausch

Zuerich (kreis 7) / Hirslanden, ZH, CH 
Experienced in Neurotoxicity Syndromes
Zuerich (kreis 7) / Hirslanden, ZH, CH 
OverviewLocationsClinical Research

Overview

Ulf Petrausch practices in Zuerich (kreis 7) / Hirslanden, Switzerland. Petrausch is rated as an Experienced expert by MediFind in the treatment of Neurotoxicity Syndromes. Their top areas of expertise are Mesothelioma, Schnitzler Syndrome, Muscle Invasive Bladder Cancer, Lymphadenectomy, and Cystectomy.

Their clinical research consists of co-authoring 47 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Neurotoxicity Syndromes.

Locations

Zuerich (kreis 7) / Hirslanden, ZH, Switzerland
Other Locations
Bern, BE, Switzerland
Zurich, ZH, Switzerland
Cham, ZG 6330, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: Recombinant intravesical BCG, Atezolizumab, Cisplatin, Gemcitabine
Study Phase: Phase 2
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
Efficacy of the Consilium Smartphone App for Detecting Symptoms and Treatment Side Effects in Cancer Patients Depending on Form of Medication Application, Age and Outpatient Characteristics: Observational Study
Efficacy of the Consilium Smartphone App for Detecting Symptoms and Treatment Side Effects in Cancer Patients Depending on Form of Medication Application, Age and Outpatient Characteristics: Observational Study
Enrollment Status: Terminated
Publish Date: February 01, 2022
Intervention Type: Device
View 3 Less Clinical Trials

47 Total Publications

Unsupervised Dynamic Electronic Patient-Reported Outcome Reporting of Immunotherapy-Related Symptoms in Cancer Patients.
Unsupervised Dynamic Electronic Patient-Reported Outcome Reporting of Immunotherapy-Related Symptoms in Cancer Patients.
Journal: Oncology
Published: March 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Petrausch's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile